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Abstract: The Hippo pathway is important for tissue homeostasis, regulation of organ size and
growth in most tissues. The co-transcription factor yes-associated protein 1 (YAP1) serves as a main
downstream effector of the Hippo pathway and its dysregulation increases cancer development
and blocks colonic tissue repair. Nevertheless, little is known about the transcriptional regulation
of YAP1 in intestinal cells. The aim of this study to identify gene control regions in the YAP1 gene
and transcription factors important for intestinal expression. Bioinformatic analysis of caudal type
homeobox 2 (CDX2) and hepatocyte nuclear factor 4 alpha (HNF4α) chromatin immunoprecipitated
DNA from differentiated Caco-2 cells revealed potential intragenic enhancers in the YAP1 gene.
Transfection of luciferase-expressing YAP1 promoter-reporter constructs containing the potential
enhancer regions validated one potent enhancer of the YAP1 promoter activity in Caco-2 and T84
cells. Two potential CDX2 and one HNF4α binding sites were identified in the enhancer by in silico
transcription factor binding site analysis and protein-DNA binding was confirmed in vitro using
electrophoretic mobility shift assay. It was found by chromatin immunoprecipitation experiments
that CDX2 and HNF4α bind to the YAP1 enhancer in Caco-2 cells. These results reveal a previously
unknown enhancer of the YAP1 promoter activity in the YAP1 gene, with importance for high
expression levels in intestinal epithelial cells. Additionally, CDX2 and HNF4α binding are important
for the YAP1 enhancer activity in intestinal epithelial cells.
Keywords: Hippo pathway; intestinal epithelium; yes-associated protein 1 (YAP1); transcriptional
regulation; gene regulation; transcription factor; cellular regulation
1. Introduction
The Hippo pathway is a signaling pathway that is important for tissue homeostasis, regulation of
organ size and tumorigenesis [1,2]. It acts as a switch between proliferation and differentiation [1,3].
Extra- and intracellular growth signals are relayed through the Hippo phosphorylation kinase cascade
that inactivates the two downstream effectors Yes-associated protein 1 (YAP1) and WW domain
containing transcription regulator 1 (WWTR1). YAP1 is a co-transcription factor that interacts with
the TEA domain transcription factor (TEAD) family members to regulate the expression of many
genes, especially those important for proliferation, adhesion, migration and the extracellular matrix
organization [4,5]. YAP1 is expressed in all human tissues, with a relatively medium expression in the
intestinal tissue [6].
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The activity of YAP1 is affected by protein–protein interactions, phosphorylation, and
re-localization of YAP1. However, little is known about the regulation of YAP1 on the transcriptional
level. SRY-box transcription factor 2 (SOX2) has been shown to be a direct transcriptional regulator of
YAP1 in osteoprogenitor cells, where SOX2 activates transcription of YAP1 without being essential for
YAP1 expression [7]. A study in hepatocellular carcinoma cells showed that knockdown of the heparan
sulfate proteoglycan Glypican-3 decreased YAP1 expression [8]. Both transcriptional regulator ERG
(ERG) and TEAD4 can interact with the YAP1 promoter and increase H3K9/14Ac acetylation which
leads to increased YAP1 expression in prostate tumors [9]. Furthermore, methylation of the YAP1
promoter in polycystic ovary syndrome (PCOS) was also shown to increase YAP1 protein levels [10].
As typical for key regulators of proliferation, YAP1 has been linked to cancer progression. Several
studies show that dysregulation of YAP1 is important in the development of colorectal cancers [11–13].
Furthermore, nuclear localization and overexpression of YAP1 have been correlated with a poor
prognosis in colorectal cancers and other cancer types [14,15]. Recently, YAP1 was shown to be
necessary for colonic tissue repair and remodeling by mediating cell reprogramming [16].
Several signaling pathways interact within intestinal epithelial cells, adding layers of complexity to
the fine-tuning of the final transcriptional regulation. The main pathways involved in the differentiation
of intestinal stem cells to the various cell lineages of the gut epithelium and homeostasis maintenance is
Wnt/β-catenin, Notch, Hedgehog, epidermal growth factor receptor (EGFR) and Bone morphogenetic
protein/transforming growth factor beta (Bmp/TGFβ), reviewed in [17,18]. The Hippo pathway
converges with several of these signaling pathways [2,19]. Well-defined networks of intestinal
epithelium-specific transcription factors control differentiation and proliferation of the intestinal
epithelium [17,20,21]. Two key regulators in these networks are Caudal Type Homeobox 2 (CDX2) and
Hepatocyte Nuclear Factor 4 alpha (HNF4α).
CDX2 is intestinal specific in adult mammals and is essential in the development and maintenance
of intestinal tissue [22,23]. Ablation of CDX2 in in vitro intestinal organoid models leads to the
development of gastric-like tissue lacking intestine-specific enzymes [24]. Dysregulation of CDX2 has
been linked to colorectal cancer development and affects the severity of disease [25,26]. Mice with
decreased CDX2 expression develop malignant tumors in the colon when treated with the DNA mutagen
azoxymethane [27]. In humans, CDX2 levels are generally lower for late-stage adenocarcinomas and
tumors with low or moderate differentiation levels [28,29].
HNF4α is highly expressed in the intestines but is also found in the liver, stomach, pancreas,
kidney, and testis [30]. HNF4α is essential for the formation of crypts in the colon and is important for
the development of the intestinal epithelium [31]. Furthermore, it regulates the expression of several
enzymes and regulators involved in metabolism in the adult gut epithelium [32,33]. HNF4α also
plays a role in cancer development but it is not well understood. One study found that some HNF4α
isoforms are lost in 40% of colorectal cancers, while another study found a general upregulation of
HNF4α in their samples [34,35].
CDX2 and HNF4α regulate each other and also auto-regulate their own expression in the
intestines [36–39]. Additionally, several other transcription factors are important in the intestinal
transcription factor network regulating intestinal development, such as the GATA-binding proteins
(GATA4/5/6), HNF1 homeobox proteins (HNF1A/B), and transcription factor 7 like 2 (TCF7L2) [17].
CDX2 interacts with the Wnt/β-catenin pathway and might be an active component of it [40].
Previous studies of the Hippo pathway have predominantly focused on the protein–protein
interactions of key kinases, which constitutes the core components of the pathway, and the role of the
main effector proteins YAP1 and WWTR1. Little is known about how the transcription of YAP1 is
controlled in intestinal tissue. This study describes a novel mechanism of transcriptional regulation of
YAP1 in intestinal cells, by the transcription factors CDX2 and HNF4α.
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2. Results
2.1. The Chromatin Landscape of the YAP1 Gene
To identify regulatory regions in the YAP1 gene chromatin immunoprecipitated followed by
sequencing (ChIP-seq) data from differentiated Caco-2 cells were analyzed for the relative abundance
of CDX2 and HNF4α. The ChIP-seq data analyzed were from Caco-2 cell precipitates with antibodies
for the transcription factors CDX2 and HNF4α as well as for histone acetylation H3K27Ac and
methylation H3K4me2 [41]. The YAP1 gene was analyzed by aligning all data tracks and then
identifying gene-regulatory regions by comparing the signal intensity from the ChIP-seq data for
transcription factors and the DNase I track which is an indicator for transcriptionally active regions
(Figure 1).
Figure 1. Putative regulatory regions within the YAP1 gene; (Top) View of the YAP1 gene region
in the February 2009 GRCh37/hg19 genome assembly at http://genome.ucsc.edu. ChIP-seq data for
CDX2, HNF4α, H3K4me2, and H3K27Ac, from confluent Caco-2 cells is shown as density graphs [39].
Circles and dashed lines indicate the promoter and intragenic regulatory regions in the YAP1 gene;
(Bottom Left) View of the promoter region of the YAP1 gene spanning 972 bp (−0.7 kb to +0.3 kb
relative to the transcription start site (TSS)); (Bottom right) View of the intragenic regulatory region
in intron 4 of the YAP1 gene spanning 599 bp (+82.2 kb to +82.8 kb relative to the TSS). The black
bars in the DNase I track [42] from Caco-2 cells represent a significant increase in DNase sensitivity in
these areas.
Three regions with clear CDX2 ChIP-seq peaks were chosen for further analysis, one region was
in the YAP1 promoter, one in intron 3 and another was in intron 4. The chosen YAP1 promoter region
spanned 972 bp located at -0.7 kb to +0.3 kb relative to the TSS (Figure 1). Clear ChIP-seq peaks were
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detected for both CDX2, HNF4α, and H3K27Ac in the promoter region, while the H3K4me2 peak was
found directly adjacent to the region.
The YAP1 intragenic region in intron 4 spanned 599 bp located at +82.2 kb to +82.8 kb relative to
the TSS (Figure 1). The intragenic region contained clear ChIP-seq signals for CDX2 and HNF4α, while
both H3K4me2 and H3K27Ac peaks were found directly adjacent.
The YAP1 intragenic region in intron 3 spanned 632 bp located at +67.5 kb to +68.3 kb relative to
the TSS (Figure 1). All three regions also contain a DNase I sensitivity signal which together with the
ChIP-seq data indicate that these are regulatory active regions (Figure 1).
2.1.1. YAP1 Promoter Activity
To analyze the gene-regulatory activity of the YAP1 intragenic region in intron 3 (+62 kb) and
4 (+82 kb) we used promoter-reporter assay analysis. We constructed luciferase reporter plasmids
containing the YAP1 promoter with or without the intragenic regions and transfected them into the
intestinal cell lines Caco-2, T84, LS174T, DLD-1, SW480, and HT-29, as well as into non-intestinal
HEK293 cells to test the YAP1 promoter activity. The cells were transfected with YAP1 reporter plasmids
with or without the intragenic regions inserted, using an empty pGL4.10 vector as a negative control
and LacZ expression plasmid for transfection efficiency control. The region in intron 3 (+62 kb) did
not show any enhancer activity (data not shown), thus we focused on characterizing the region from
intron 4 in further in vitro analyses.
pGL4.10 generated a very low background signal in all cell lines (Figure 2). Luciferase activity
of the pGL4.10-YAP1 promoter construct was 7 to 30-fold above background for all of the cell lines,
revealing that the YAP1 promoter is active in both intestinal and non-intestinal cells.
Figure 2. Relative luciferase/β-galactosidase activity from cell lysates of the intestinal cell lines
Caco-2, T84, LS174T, DLD-1, SW480, and HT-29 transfected with pGL4.10 luciferase reporter constructs
containing the YAP1 promoter and +82 kb enhancer. HEK293 cells are used as a non-intestinal control.
Vertical lines separate data from independent assays. Bars are mean values on a log2 scaled y-axis, with
error bars showing SD, n = 4). + indicates that either the YAP1 promotor or enhancer sequence was
inserted in to the luciferase construct sequence. Statistical significance was obtained using one-way
ANOVA with p-values under 0.001 (***) and 0.0001 (****)
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Transfections with the pGL4.10-YAP1 promoter+enhancer (+82 kb intragenic region) construct in
Caco-2 and T84 cells showed an increase in reporter gene activity compared to pGL4.10-YAP1 promoter
levels of 9.5-fold, and 2.7-fold, respectively. No increase in activity was detected in any of the other cell
lines. Together, this data shows that the +82 kb intragenic region functions as an enhancer of YAP1 in
Caco-2 and T84 cells. Interestingly, these two cells lines are the only intestinal cell lines that share the
ability to spontaneously differentiate upon confluency.
Analysis of ChIP-seq data from Caco-2 cells revealed that CDX2 and HNF4α are associated with
regions in the YAP1 gene and thus might be potential regulators of the expression of the YAP1 gene.
Locating specific binding sites for CDX2 and HNF4α in the YAP1 promoter or +82 kb enhancer is
necessary to be able to determine if they exert their regulation by specifically binding to the DNA.
The JASPER algorithm predicted two CDX2 sites, and two HNF4α sites in the promoter region
while three CDX2 and two HNF4α sites were found in the +82 kb enhancer by using the transcription
factor binding site matrices MA04665.1 for CDX2 and MA0114.2 for HNF4α (Table S1).
Due to their high scores in the in silico analysis, three sites in the YAP1 enhancer were selected
for further analysis. These were two CDX2 sites (“CDX2-S1” and “CDX2-S2”) and one HNF4α site
(“HNF4α”).
To determine the potential importance of the three putative binding sites we aligned genomic
DNA sequences from eight vertebrate species and compared the evolutionary conservation of the
binding sites on the basis of the transcription factor binding site matrices for CDX2 and HNF4α
(Figure 3A). The analysis showed conservation among the analyzed vertebrates except for in mice, in
which the binding sites are not preserved.
We used electrophoretic mobility shift assay (EMSA) to determine whether the two CDX2 and
the one HNF4α in silico predicted transcription factor binding sites were functional and could bind
endogenous proteins in Caco-2 cells. Oligonucleotides for each of the three binding sites were designed
and 32P-radiolabeled. Unlabeled oligonucleotides with mutated binding sequences and a non-specific
competitor were used as competitors (Table S3).
Clear specific complexes were formed on all three EMSAs when radiolabeled oligonucleotides
were combined with the Caco-2 nuclear extract. Unlabeled oligonucleotides were able to compete for
the binding of the radiolabeled oligonucleotides for all three sites, while the non-specific competitor
was not which indicates that the protein-oligonucleotide complexes are specific.
Two protein-DNA complexes were formed between the oligonucleotide containing the CDX2-S1
site (Figure 3B), and proteins in the Caco-2 extract, while only one complex was formed using
the CDX2-S2, or HNF4α radiolabeled oligonucleotides (Figure 3C) and (Figure 3D), respectively.
Oligonucleotides with mutated binding sites were not able to compete for binding with the radiolabeled
probe. However, the mutation in the HNF4α site did not completely destroy the binding ability for the
mutated oligonucleotide as it slightly reduced binding to the probe (Figure 3D, lane 4).
When antibodies to CDX2, HNF4α or a negative control hemagglutinin (HA) were added, only
CDX2 and HNF4α produced supershifts, demonstrating that they are part of the protein-radiolabeled
oligonucleotide complexes. In conclusion, the EMSA revealed two CDX2 and one HNF4α binding
sites in the YAP1 +82 kb enhancer.
We wanted to investigate the effect of CDX2 and HNF4α on the YAP1 +82 kb enhancer activity
in Caco-2 cells. This was done by mutating the two CDX2 and one HNF4α binding sites that were
confirmed to be functional in the EMSA analysis, in the pGL4.10-YAP1 promoter+enhancer constructs
by site-directed mutagenesis (Figure 4). Three constructs were created by mutation of three binding
sites. CDX2-S1 (M1), CDX2-S2 (M2) and HNF4α (M3) were constructed and assayed for luciferase
activity. The CDX2-M1 construct decreased the +82 kb enhancer effect more than 5-fold, p < 0.0001,
while CDX2-M2 only decreased activity by 1.4-fold, p < 0.01. Removing the HNF4α site (M3) caused
a 2-fold decrease in activity. This shows that the CDX2-S1 site is important for the +82 kb enhancer
activity in Caco-2 cells and that both CDX2-S2 and the HNF4α site also contribute to the activity.
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Figure 3. Electrophoretic mobility shift assay and conservation analysis of two CDX2 binding sites
and one HNF4α binding site in the YAP1 +82 kb enhancer named CDX2-S1 and CDX2-S2 and HNF4α.
(A) Alignment of eight vertebrate sequences to identify evolutionary conservation at three detected
transcription factor binding sites in the YAP1 +82 kb enhancer. The dotted lines indicate the borders
of the zoomed in-areas and the grey color indicates fully conserved bases that are identical to the
human bases; (B,C,D) All samples contain: 1 µL nuclear extract from differentiated Caco-2, 2.5 fmol
radioactive labeled probe (unbound probe is seen in the bottom of the image), and 0.5 µg poly(dI-dC)
as a competitor for nonspecific DNA binding proteins. (B) In addition, lane 2 contains a non-specific
DNA-oligo competitor; lane 3 contains non-labeled CDX2-S1 competitor oligo; lane 4 contains mutated
non-labeled competitor oligo CDX2-S1-Mut; lane 5 contains CDX2 specific antibody (αCDX2); lane 6
contains anti-hemagglutinin (α HA) control antibody; (C) Same as in B, but with CDX2-S2 oligo and
CDX2-S2-Mut oligo; (D) Same as in C, but with HNF4α oligo, HNF4α-Mut oligo, and anti-HNF4α
antibody (αHNF4α).
Next, we performed an overexpression study, where the pGL4.10-YAP1 promoter plasmid with
or without the +82 kb enhancer was co-transfected with CDX2 and HNF4a expression plasmids to
elucidate their effect on the transcriptional regulation of YAP1 in Caco-2 cells. The relative luciferase
activity was normalized to the pGL4.10-YAP1 promoter plasmid. The activity of the pGL4.10-YAP1
promoter plasmid was not affected by overexpression of CDX2 but was increased 2-fold by HNF4α
overexpression (Figure 5).
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Figure 4. Relative luciferase/β-galactosidase activity from cell lysates of Caco-2 cells transfected with
pGL4.10 luciferase reporter constructs containing the YAP1 promoter and +82 kb enhancer with or
without mutated CDX2 and HNF4α binding sites. The sequence of the three mutated binding sites
CDX2 site 1 (M1), CDX2 site 2 (M2), and HNF4α (M3) is depicted below on the figure. Relative luciferase
activity was normalized to the empty pGL4.10 vector. Bars are mean values on a log2 scaled y-axis
with SD error bars. + indicates the presence of a YAP1 promotor or enhancer sequence in the luciferase
reporter sequence. The bold bases at the bottom indicates the core sequence of the transcription factor
binding site and mutated core sequences are underlined. Statistical significance was obtained using
two-tailed unpaired student’s T-test with p-values under 0.01 (**), 0.001 (***), and 0.0001 (****), n = 4.
Figure 5. Relative luciferase/β-galactosidase activity from cell lysates of Caco-2 cells transfected
with pGL4.10 luciferase reporter constructs containing the YAP1 promoter and/or +82 kb enhancer.
Cytomegalovirus (CMV)-HNF4α, CMV-CDX2 expression vector or an empty CMV vector were
co-transfected with the pGL4.10 plasmids for the overexpression of HNF4α and CDX2. The relative
luciferase/β-galactosidase activity was normalized to the pGL4.10-YAP1 promoter construct. Bars are
mean values plotted on a log2 scaled y-axis, with error bars showing 95% CI. + indicates the presence
of a YAP1 promotor or enhancer sequence in the luciferase reporter sequence, or the addition of a
CMV-based expression vector to the transfection. Data are statistically significant using two-tailed
unpaired student’s T-test with p-values under 0.001 (***), n = 4.
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Overexpression of HNF4α with the pGL4.10-YAP1 promoter+enhancer plasmid increased the
activity of the already powerful +82 kb enhancer more than 6-fold, yielding more than a 75-fold
difference from the pGL4.10-YAP1 promoter plasmid alone. It was clear that HNF4α acted as a strong
activator of YAP1 expression via the YAP1 +82 kb enhancer. Interestingly, overexpression of CDX2 did
not increase the activity of the pGL4.10-YAP1 promoter+enhancer plasmid but instead displayed an
inhibitory role towards the activity. This result does not correlate with the decrease in activity that was
seen when the CDX2 binding sites were mutated (Figure 4). The lack of effect when overexpressing
CDX2 and analyzing enhancer activity in Caco-2 cells has previously been observed with other CDX2
regulated genes [43].
2.1.2. CDX2 and HNF4α Binding Sites in the YAP1 Intragenic Enhancer
We performed quantitative PCR on ChIP DNA from Caco-2 cells to determine the relative
abundance of CDX2 and HNF4α bound to the YAP1 +82 kb enhancer (Figure 6). The relative
abundance of immunoprecipitated DNA was compared to negative control DNA precipitated with
Hemagglutinin (HA) antibody. Primers were designed to span a small region in the YAP1 +82 kb
enhancer with a clear ChIP-seq peak for CDX2 and HNF4α (Table S2-B). The relative abundance of
YAP1 +82 kb enhancer CDX2 immunoprecipitated DNA was 0.211% of total input DNA, which was
a more than a 100-fold increase over the HA control ChIP level (0.002%). For HNF4α the relative
abundance was 0.035% of total input DNA, which was a ~17-fold increase over the HA control ChIP
level. Both CDX2 and HNF4α binding were substantially increased compared to the negative control
which indicates that both transcription factors bind to the YAP1 +82 kb enhancer in Caco-2 cells.
Figure 6. PCR quantification of Caco-2 DNA immunoprecipitated with either anti-CDX2 (αCDX2)
or anti-HNF4α (αHNF4α) or control anti-hemagglutinin (αHA) antibodies. The amount of purified
Caco-2 ChIP DNA was compared to the amount of input DNA (non-immunoprecipitated) in the YAP1
+82 kb enhancer, using specific primers (Table S2-B). Quantification was performed by ChIP-qPCR and
bars represent mean values with range, n = 2.
2.1.3. CDX2 Activation of YAP1 Protein Expression
Western blotting analysis was used to assess whether the transcriptional regulation of YAP1 by
CDX2 seen in the promoter assays could be translated to the protein level. Caco-2 cells are dependent
on CDX2 expression and thus they are not suitable for knockdown experiments [39,44]. However,
an intestinal CDX2 knockout cell line was recently constructed using the LS174T colon cancer cell
line [45]. We aimed to compare the CDX2 and YAP1 protein expression in intestinal and non-intestinal
cells as well as in intestinal cells with or without CDX2, to clarify the regulatory role of CDX2 on
the YAP1 protein expression. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a
control to measure total protein loaded from the confluent Caco-2, HeLa, LS174T, and LS174T CDX2
knockout cells.
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CDX2 expression was detected in both the LS174T wildtype and Caco-2 cells but not in HeLa cells
or the LS174T CDX2 knockout cells (Figure 7). The YAP1 expression was high in Caco-2 cells, lower
in LS174T wildtype cells and LS174T CDX2 knockout cells, but was undetected in the non-intestinal
HeLa cells. Interestingly, YAP1 expression was present in LS174T knockout cells with no CDX2,
demonstrating that CDX2 expression is not essential for YAP1 expression in LS174T cells. This is in
line with the finding that the YAP1 +82 kb enhancer is not active in LS174T cells (Figure 4) and that
CDX2, thus, only have limited effect on the basic YAP1 promoter activity.
Figure 7. Comparison of CDX2 and YAP1 protein expression using Western blotting, using
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a reference. Cell lysates are from confluent
cells from the intestinal cell lines Caco-2 and LS174T with and without CDX2 knockout (KO), as well as
the non-intestinal cell line HeLa. All bands are from the same gel and images were globally adjusted
for contrast and brightness.
3. Discussion
The Hippo pathway controls proliferation and differentiation in many tissues partly through
YAP1. Dysregulation of YAP1 often leads to development or exacerbation of diseases specific to the
tissue in question. While the effects of YAP1 dysregulation in the intestine has been studied, virtually
no papers have been published on the transcriptional regulation of YAP1. More in-depth knowledge
about the regulation of YAP1 in the intestine will increase the understanding of the role of YAP1 and
the Hippo pathway in the intestine.
Through a combination of bioinformatic analysis of ChIP-seq data and transfection with luciferase
promoter-reporter expression constructs containing the YAP1 promoter, we identified a powerful
+82 kb enhancer of YAP1 that was functional in the intestinal cell lines Caco-2 and T84. However,
the +82 kb enhancer did not seem to be functional in four other intestinal cell lines DLD-1, SW480,
HT-29, and LS174T (Figure 2). Interestingly, Caco-2 and T84 are the only intestinal cell lines that have
the ability to spontaneously differentiate into monolayers of functionally and structurally mature
absorptive epithelial cells with microvilli and expression of many brush border enzymes [46,47].
Whereas HT-29 cells are able to differentiate when grown under special culture conditions, LS174T and
SW480 cells form multilayers without epithelial polarity or enterocytic differentiation, whatever the
culture conditions [47–49]. Therefore, we hypothesize that the similarity of Caco-2 and T84 cells to
normal intestinal cells might mean that only they have retained the cellular environment needed for
the YAP1 +82 kb enhancer to be functional.
Previous studies have reported SOX2, ERG, TEAD4, and glypican 3 as regulators of YAP1
expression in osteoprogenitor, hepatic, or prostate tissue. While some detected epigenetic changes to
the YAP1 promoter, none of them identified intragenic regulatory regions or specific binding sites in
the YAP1 gene [7–10]. Here we present the first clear evidence of an enhancer in the YAP1 gene that is
active in intestinal cells.
We measured the importance of HNF4α and CDX2 for the YAP1 promoter activity in intestinal cell
lines. By mutation of binding sites and promoter/enhancer experiments in Caco-2 cells, we have shown
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that both CDX2 and HNF4α are involved in activation of the YAP1 promoter activity. Promoter-reporter
assays with mutated CDX2 and HNF4α binding sites in the YAP1 +82 kb enhancer showed that
these sites were important for the enhancer activity (Figure 4). HNF4α overexpression resulted in
significantly increased activity of the YAP1 +82 kb enhancer (Figure 5). It was, however, somewhat
surprising that CDX2 overexpression did not increase the reporter gene expression. However, we
have previously seen that CDX2 overexpression in Caco-2 cells, which have a high endogenous level
of CDX2 [39], does not necessarily result in increased reporter gene expression when CDX2 binds to
enhancer regions [43].
HNF4α and CDX2 are essential components of the intestinal transcription factor network that
controls development and homeostasis, and CDX2 is normally only expressed in the intestines after birth
in mammals [50,51]. During intestinal differentiation, CDX2 and HNF4α are a part of a transcription
factor network that tightly regulates a large array of intestinally expressed genes [17,20,36]. YAP1 is
expressed in several tissues but is especially highly expressed in colon cancers [12,13]. We suggest
that CDX2 and HNF4α adds an intestinal-specific layer of control to the Hippo pathway through the
transcriptional regulation of the YAP1 gene.
Using Western blot analysis to measure YAP1 and CDX2 protein expression in LS174T cells with
and without CDX2 knockout, we found that CDX2 is not necessary for basic YAP1 expression in
these cells. Caco-2 cells have higher levels of both CDX2 and YAP1 protein expression than LS174T.
Although the transcriptional regulation of YAP1 is complex, we suggest that a part of the explanation
for increased expression is due to CDX2 binding to the intronic +82 kb enhancer in Caco-2 cells.
By constructing HNF4α knockout intestinal cells lines, it would be possible to determine how
important HNF4α is for the general transcription of YAP1 and its precise contribution to the +82 kb
enhancer effect. Although this might not be possible since it has not been possible to find any published
work describing an HNF4α knockout intestinal cell line and our lab has not been able to create
one either.
In summary, we have identified a promoter region in the YAP1 gene with importance for the
transcriptional activation of YAP1 in all tested cell lines. Furthermore, we identified a YAP1 +82 kb
enhancer with functional CDX2 and HNF4α binding sites that increases YAP1 promoter activity in
Caco-2 and T84 cells.
4. Materials and Methods
4.1. Culture of Human Cell Lines
Caco-2, T84, DLD-1, SW480, HT-29, and LS174T wildtype, colon adenocarcinoma cell line; HEK293,
human embryonic kidney cell line; HeLa, cervical adenocarcinoma cell line; LS174T derived CDX2
knockout (LS174T CDX2 knockout) cell line [45] were grown in T175 culture flasks in Dulbecco’s
Modified Eagle Medium (Lonza, Basel, Switzerland) or RPMI-1640 for DLD-1 (Thermo Fisher Scientific,
Waltham, MA, USA), added 10% Fetal Bovine Serum gold (PAA) and 100 U/mL Penicillin-Streptomycin.
Cells were incubated at 37 ◦C in 5% CO2 and passaged every 3–4 days when ~80% confluent. Passaging
was done by removing media, rinsing three times with 85 mM sodium citrate, adding 1mL 0.05%
trypsin EDTA (Invitrogen, Carlsbad, CA, USA) and incubating 5 min at 37 ◦C in 5% CO2.
4.2. Bioinformatic Analysis of the YAP1 Gene
The YAP1 gene (NM_001130145) was analyzed to identify transcriptionally active regions using the
UCSC Genome Browser (Feb. 2009 GRCh37/hg19 assembly). ChIP-seq data were imported as custom
tracks from Caco-2 cell precipitates with antibodies for the transcription factors CDX2 and HNF4α as
well as for histone acetylation H3K27Ac and methylation H3K4me2 [41]. Additionally, the ENCODE
dataset for DNase I activity [42] as well as the UCSC track for 46-way multiple alignment of vertebrate
genomes for conservation analysis was also imported. The location of CDX2 and HNF4α binding sites
in the YAP1 promoter region (−0.7 kb to +0.3 kb relative to the TSS; chr11:101,980,493-101,981,464),
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the intron 1 region (+1.1 kb to +3.2 kb relative to the TSS; chr11:101982249-101983075), the intron 3
region (+67.5 kb to +68.3 kb relative to the TSS; chr11:102048671-102049303) and the intron 4 enhancer
(+82.2 kb to +82.8 kb relative to the TSS; chr11:102,063,361-102,063,959) was predicted using an in silico
analysis using the online transcription factor database JASPAR (URL: http://jaspar.genereg.net) [52].
The analysis was carried out using the MA0465.1 (URL: http://jaspar.genereg.net/matrix/MA0465.1/)
and the MA0114.2 (URL: http://jaspar.genereg.net/matrix/MA0114.2/) matrices for CDX2 and HNF4α,
respectively with a relative score cutoff of 75% to 85%. The location of the binding sites in the genome
is given relative to the transcription start site (TSS) of YAP1 at chr11:101,981,192.
4.3. Construction of Luciferase Reporter Constructs
The YAP1 promoter and +82 kb enhancer sequence were PCR amplified and gel purified with
primers ordered from Eurofins Genomics (Eurofins Genomics, Ebersberg, Germany) (Table S2-A).
pGL4.10 vector (Promega, Madison, WI, USA) was digested with HindIII and gel purified. In-Fusion
cloning (Clontech, Fremont, CA, USA) was carried out according to the manufacturer’s protocol, using
gel-purified linearized pGL4.10 vectors and promoter insert in a 1:2 molar ratio. 2.5µl cloning reaction
was used for transformation of One Shot TOP10 chemically competent E. coli (Thermo Fisher Scientific,
Waltham, MA, USA). Colonies were isolated and sequenced (Beckman Coulter Genomics, Brea, CA,
USA). For the construction of the pGL4.10-YAP1 promoter+enhancer plasmid, the pGL4.10-YAP1
promoter plasmid was digested with SalI restriction endonuclease and gel purified, and In-Fusion
cloned with enhancer insert using the same procedure.
4.4. Construction of Reporter Constructs with Mutated Binding Sites
pGL4.10-YAP1 promoter+enhancer fragments with mutated binding sites were created by PCR
amplifying forward primers containing mutated binding sites, with reverse primers containing
In-Fusion tails and vice versa. The products were subsequently combined in a third PCR amplification.
Mutated inserts were In-Fusion cloned and transformed. Plasmids were purified and digested with
PstI, XhoI, or XbaI and the fragments were gel purified and sequenced.
4.5. Transfection of Cell Lines
Cells were seeded in 24 well plates at 50,000 cells/well (Caco-2, DLD-1, SW-480, and HT-29) or at
100,000 cells/well (HEK293, LS714T, and LS174T CDX2 KO cells) and transfected after 24 h. For each
well, a transfection mixture of 50 µl DNA/polyethyleneimine (PEI) mix was prepared, consisting of
2 µM PEI (Alfa Aesar Haverhill, MA, USA) diluted in 150 mM NaCl to 25 µl and 300 ng plasmid
DNA diluted with 150 mM NaCl to 25 µl. The transfection mix contained: 25 ng cytomegalovirus
(CMV) promoter-driven expression plasmid for CDX2 or HNF4α, 25 ng of an empty CMV expression
plasmid that was added to equalize for the amount CMV promoter constructs in the experiments
without overexpression, 50 ng promoter-reporter plasmid, 25 ng CMV-LacZ plasmid for internal
control of transfection efficiency, and 200 ng pBluescript SK+ II as inactive DNA to reach 300 ng
DNA/well. Volume was adjusted with 150 mM NaCl and transfection mix was incubated 60 min at
room temperature. The transfection mix was added in a dropwise fashion to wells, followed by light
shaking. After transfection, plates were centrifuged at 200 g for 5 min and incubated overnight at 37 ◦C
and 5% CO2. The media was changed after 24 h, and cells were grown for an additional 24 h before
assayed for luciferase and β-galactosidase activity. All transfection experiments were carried out at
least twice with n = 4.
4.6. Measuring Luciferase Activity of Reporter Constructs
Measurements were carried out on a GloMax®96 Microplate Luminometer using the Dual-Light™
Luciferase and β-Galactosidase Reporter Gene Assay System (Thermo Fisher Scientific, Waltham, MA,
USA). Cells were rinsed three times with 1X phosphate buffered saline (PBS) and lysed with 130 µL
TROPIX lysis solution containing 0.5 mM DTT and incubated for 10 min on ice. 10 µL lysate was
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transferred to a 96 well GloMax Luminometer Light Plate (Promega, Madison, WI, USA), and luciferase
activity was measured using a 5-sec integration time and a 2-sec delay. The β-galactosidase activity
was measured 45 min after luciferase activity.
4.7. Chromatin Immunoprecipitation Assay and Quantitative PCR
Two separate immunoprecipitations from Caco-2 cells were generated and the experiment was
run twice with three technical replicates. Both were prepared following the protocol described in [53].
The sets included CDX2, HNF4α, and Hemagglutinin (HA) precipitations and were generated using
the antibodies; CDX2 (BioGenex, Freemont, CA, USA, MU392A-UC), HA (Santa Cruz Biotechnology,
Santa Cruz, CA, USA, Clone Y-11 X, SC-805 X), or HNF4a (Santa Cruz Biotechnology, Clone SC 171 X,
SC-8987 X). qPCR was used to detect binding of CDX2, HNF4α, and HA to the YAP1 promoter and
+82 kb enhancer in the samples, using primers from (Eurofins Genomics, Ebersberg, Germany) (Table
S2-B). qPCR was carried out with SsoFast EvaGreen Supermix with Low 6-carboxy-X-rhodamine (ROX)
(Bio-Rad, Hercules, CA, USA) on 1 µl (1/20th of total immunoprecipitated (IP) sample DNA) ChIP DNA
or H2O with 0.5 µM primers on a Stratagene MX3005P real-time thermal cycler (Agilent Technologies,
Santa Clara, CA, USA). Relative quantification of ChIP DNA was calculated as a percentage of the
input DNA by the delta-delta Ct method [54].
4.8. Electrophoretic Mobility Shift Assay
Oligonucleotides for the EMSA was generated with 5′ overhangs and containing either the
wildtype binding sequences, a non-specific competitor sequence, or specific competitor sequences
with mutated binding sites (Table S3). 250 pmol of each complementary oligonucleotide was annealed
in a total volume of 100 µL 0.1 M NaCl by heating to 95 ◦C followed by passive cooling until
room temperature.
For the preparation of radiolabeled oligonucleotides 2.5 pmol annealed oligonucleotide pairs
were mixed with 0.5 µL T4 Polynucleotide Kinase, 1 µL 10X forward kinase buffer, 5 µL [γ-32P]-ATP
(3000Ci/mmol 5 mCi/ml EasyTide Lead) (PerkinElmer, Waltham, MA, USA) and 2.5 µL H2O for a total
volume of 10 µL. The reaction was incubated at 37 ◦C for 30 min after which 20 µL 1X Tris-EDTA
(TE) buffer (10 mM Tris-HCl (pH 8.0), 0.1 mM EDTA) was added. The probes were purified with
Illustra MicroSpin G-25 Columns (GE Healthcare Life Sciences, Marlborough, MA, USA) and diluted
with 1X TE buffer to a total volume of 100 µL and a concentration of about 25 fmol/µL. Radiolabeled
oligonucleotides were further diluted 10X in TE buffer immediately before loading.
Caco-2 nuclear extracts used for the EMSA was prepared as previously described [55]. The EMSA
reaction contained 1 µl differentiated Caco-2 nuclear extract 4 µl dialysis buffer (25 mM Hepes pH 7.6,
0.1 mM EDTA, 40 nM KCl, and 10% glycerol), 10 µl Gel-shift buffer (25 mM Tris-HCl pH 7.5, 5 mM
MgCl2, 5% Ficoll 400, 2.5% glycerol, 60 mM KCl, 0.5 mM EDTA, 1 mM DTT, and protease inhibitors),
and 0.5 µl dI-dC (homopolymer of deoxyinosine and deoxycytidine). For competition 1 µL 250 fmol/µL
unlabeled oligonucleotides, either non-specific, wildtype, or mutated oligonucleotides were added.
Supershift assays contained 1 µL antibody; CDX2 (BioGenex, Freemont, CA, USA, MU392A-UC), HA
(Santa Cruz Biotechnology, Santa Cruz, CA, USA, Clone Y-11 X, SC-805 X), or HNF4a (Santa Cruz
Biotechnology, Santa Cruz, CA, USA, Clone SC 171 X, SC-8987 X). The reaction was incubated 20 min
on ice, and then added 1 µL 2.5 fmol of 32-P labeled probe followed by 20 min incubation on ice.
Before gel-loading, 2 µl Gel-shift loading buffer (10% glycerol, 0.2% Bromphenol blue and 0.5X
Tris-borate-EDTA buffer (2X TBE, 44.5 mM Tris-HCl pH 8.0, 1 mM EDTA, and 44.5 mM boric acid))
was added to the reaction mix. The reaction mix was loaded on a precooled non-denaturing 5%
polyacrylamide gel (1 gel: 2.25 mL 30% Acrylamide/Bis-acrylamide (29:1), 0.67 mL 10X TBE, 0.78 mL
87% glycerol, 9.71 mL H2O, 54 µL 25% ammonium persulfate (AMPS), and 6.9 µL TEMED), using
precooled 0.5X TBE as running buffer. Runtime was 45 min at 100 mV and 25 mA/gel with active
cooling. The gel was dried on a slab gel dryer for two hours and exposed on a phosphor-imager
for 24 h. The phosphor screen was scanned on a Storm 840 scanner (GE Healthcare Life Sciences,
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Marlborough, MA, USA) and the image was processed using the Image-Quant Software version 5.2
(GE Healthcare Life Sciences, Marlborough, MA, USA).
4.9. Western Blotting
Protein extraction was carried out on cells seeded in 6-well plates at 100,000/well for Caco-2,
300,000/well for LS174T wildtype and LS174T CDX2 KO cells. 48 h after seeding, the media was
changed and at 72 h cells were rinsed with cold PBS and lysed for 15 min with 100 µl/well 1X RIPA
lysis buffer (1X PBS, 300 mM NaCl, 1% Tergitol NP-40, 0.1% SDS, 0.5% 7-Deoxycholic acid sodium
salt, 0.5 µM EDTA pH 8.0) with freshly added 1 mM DTT and 2 µL/mL protease inhibitor mix p8340
(Sigma-Aldrich, St. Louis, MO, USA). Lysates were centrifuged for 20 min at 12.000 g at 4 ◦C and
supernatant saved at −20 ◦C. Protein concentration was determined by Bradford analysis (Bio-Rad,
Hercules, CA, USA).
10 µg or 20 µg protein was mixed 1:4 (v/v) with Bolt loading buffer and 1:10 (v/v) with Bolt sample
reducing agent. Samples were incubated at 70 ◦C for 10 min and loaded on a Bolt 4–12% Bis-Tris Plus
gel (Thermo Fisher Scientific, Waltham, MA, USA) along with prestained protein marker PageRuler
(Thermo Fisher Scientific, Waltham, MA, USA). SDS-PAGE was performed in 1X Bolt MOPS running
buffer, (Thermo Fisher Scientific, Waltham, MA, USA) for 50 min at 150 V. Gels were transferred by
wet-electrotransfer to PVDF membranes for 75 min at 25 V and 100 mA in 1X NuPage transfer buffer,
(Thermo Fisher Scientific, Waltham, MA, USA). Membranes were blocked with dry skim milk diluted
to 5% in Wash buffer (1X PBS with 0.1% Tween-20) for 1 h at room temperature, washed with Wash
buffer 3 times for 7 min and incubated overnight at 4 ◦C with primary antibody diluted in Dilution
buffer (2.5% skim milk in Wash buffer). Membranes were washed 3 times for 7 min and incubated with
secondary antibody for 1 h at room temperature and washed 3 times for 7 min. Bands were visualized
by incubating with the ECL solution SuperSignal™ West Dura Extended Duration Substrate (Thermo
Fisher Scientific, Waltham, MA, USA). Antibodies used: CDX2 1:2000, BioGenex, Freemont, CA, USA,
MU392A-UC); YAP1 1:15,000, (Abcam, Cambridge, UK, ab52771); GAPDH 1:30,000 (Fitzgerald, North
Acton, MA, USA, 10R-G109a), Goat anti-rabbit HRP 1:4000 (Thermo Fisher Scientific, Waltham, MA,
USA, 32260); Goat anti-mouse HRP 1:10,000 (Thermo Fisher Scientific, Waltham, MA, USA, 32230).
4.10. Statistics
Where applicable, values are represented by mean values with 95% confidence intervals or SD
values. The p-values have been determined by two-tailed Student’s t-tests or one-way ANOVA using
GraphPad Prism v7.0 (GraphPad Software, San Diego, CA, USA). The significance levels are shown as
* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Supplementary Materials: Supplementary Materials can be found at http://www.mdpi.com/1422-0067/20/12/
2981/s1.
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Abbreviations
YAP1 Yes-associated protein 1
WWTR1 WW domain containing transcription regulator 1
TEAD TEA domain transcription factor
ERG Transcriptional regulator ERG
TEAD4
HA
TEA domain transcription factor 4
Hemagglutinin
PCOS
GAPDH
Polycystic ovary syndrome
Glyceraldehyde-3-phosphate dehydrogenase
GATA4/5/6 GATA-binding proteins 4/5/6
HNF1A/B HNF1 homeobox proteins
TCF7L2 Transcription factor 7 like 2
HNF4α Hepatocyte nuclear factor 4 alpha
CDX2 Caudal type homeobox 2
EMSA Electrophoretic mobility shift assay
HA Hemagglutinin
PEI Polyethyleneimine
AMPS Ammonium persulfate
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